Lupin has announced its fourth quarter results. The company's Q4 net profit was at Rs 96 crore versus 141.10 crore. Kamal K Sharma, MD, Lupin said that Kyowa was acquired somewhere in the first week of October and therefore it is supposed to contribute this year in substantial measure. He feels that the company would earn around 370 crore for the topline as well as the bottomline.

Excerpts from CNBC-TV18’s exclusive interview with Kamal K Sharma, MD of Lupin

Q: Can you tell us what accounted for the smart jump in operating profit margins (OPM) this year as well as the near 40%-42% jump in revenues in the current quarter?

A: I think for the overall growth in the business, major contribution has come from advanced markets. United States and Europe have contributed 30% of our revenue, which is a high margin business. In addition our domestic growth has been very robust, we have grown 26% in India from Asian markets. So overall I think it is the growth in all sectors of our business.

Q: Can you also tell us how much growth has come from your Kyowa acquisition?

A: That is not a substantial part this year because Kyowa was acquired somewhere in the first week of October and therefore what you get to see is only part of the year. But that is supposed to contribute this year in substantial measure.

Q: How much do you expect contribution in FY09, how much can we see Kyowa contributing in this year?

A: I think it is probably around 370 crore to the topline and commensurate in the bottomline also.

Q: How many new product launches will we see in Japan through Kyowa?

A: Certainly 10 approvals that we have got recently, those will be launched and we are augmenting research efforts from Lupin’s Research Park also. So going forward our endeavour is that the regular launch, which was about four-five every year, should doubled now on.

Q: Also tell us about your three big launches, Cefdinir, Lisinopril and Suprax. How much market share are you still retaining on these three and going forward are you seeing competition intensifying on all these three?

A: We are market leaders in Lisinopril and our market share is almost around 40%, Cefdinir we are in the range of around 15% and Suprax is doing very well. I think last year we did about USD 24 million and this year we have done about USD 36 million, and we see 60% growth this year.